RCUS on NYSE
Arcus Biosciences
Biopharmaceutical company.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2015Founded1
Compare with Zomedica Corp., BIOHARVEST SCIENCES INC. or Verastem Oncology, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-1169.7%Operating margin4
-1069.7%Net margin4
-35.3%Revenue growth, 20254
-55.9%Return on equity4
0.16×Debt to equity4
-$484.0MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License And Development Services brought in 89% of the revenue Arcus Biosciences broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| License And Development Services | $80.0M | $222.0M | $221.0M |
| Other Collaboration Revenue | $37.0M | $36.0M | $26.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$523.0M
Out of $33.0M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development (Includes $25, ($39) and ($110) payments to/(from) a related party) | $523.0M | $448.0M | $340.0M |
| Impairment of long-lived assets (see Note 14, Leases) | $0 | $20.0M | $0 |
| Total operating expenses | $633.0M | $588.0M | $457.0M |
| Loss from operations | -$386.0M | -$330.0M | -$340.0M |
| Interest and other income, net | $41.0M | $52.0M | $41.0M |
| Interest expense | -$8.0M | -$4.0M | -$2.0M |
| Total non-operating income, net | $33.0M | $48.0M | $39.0M |
| Loss before income taxes | -$353.0M | -$282.0M | -$301.0M |
| Income tax expense | $0 | -$1.0M | -$6.0M |
| Net loss | -$353.0M | -$283.0M | -$307.0M |
| Net loss per share, basic (in dollars per share) | -$3.29 | -$3.14 | -$4.15 |
| Net loss per share, diluted (in dollars per share) | -$3.29 | -$3.14 | -$4.15 |
| Shares used to compute net loss per share, basic (in shares) | 107.4M shares | 90.1M shares | 74.0M shares |
| Shares used to compute net loss per share, diluted (in shares) | 107.4M shares | 90.1M shares | 74.0M shares |
| Revenues | $247.0M | $258.0M | $117.0M |
| General and administrative expense | $110.0M | $120.0M | $117.0M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $222.0M | $150.0M | |
| Marketable securities | $759.0M | $828.0M | |
| Prepaid expenses and other current assets | $15.0M | $18.0M | |
| Total current assets | $1.0B | $1.0B | |
| Long-term marketable securities | $29.0M | $14.0M | |
| Property and equipment, net | $40.0M | $47.0M | |
| Other noncurrent assets | $63.0M | $73.0M | |
| Total assets | $1.1B | $1.1B | |
| Other current liabilities | $154.0M | $123.0M | |
| Total current liabilities | $231.0M | $226.0M | |
| Deferred revenue, noncurrent ($43 and $234 to a related party) | $43.0M | $234.0M | |
| Long-term debt | $99.0M | $48.0M | |
| Other noncurrent liabilities | $135.0M | $157.0M | |
| Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 125.3 shares in 2025 and 92.2 shares in 2024 issued and outstanding | $2.1B | $1.6B | |
| Accumulated deficit | -$1.5B | -$1.1B | |
| Total stockholders equity | $631.0M | $485.0M | $462.0M |
| Total liabilities and stockholders equity | $1.1B | $1.1B | |
| Receivable from collaboration partners, current | $11.0M | $20.0M | |
| Accounts payable, current | $42.0M | $18.0M | |
| Deferred revenue, current | $35.0M | $85.0M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in shares) | 125.3M shares | 92.2M shares | |
| Common stock, shares outstanding (in shares) | 125.3M shares | 92.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$353.0M | -$283.0M | -$307.0M |
| Stock-based compensation expense | $60.0M | $76.0M | $73.0M |
| Depreciation and amortization | $10.0M | $10.0M | $8.0M |
| Noncash lease expense | $7.0M | $7.0M | $8.0M |
| Impairment on right-of use assets | $0 | $20.0M | $0 |
| Amortization of discounts on marketable securities | -$13.0M | -$25.0M | -$19.0M |
| Other items, net | $1.0M | $3.0M | $2.0M |
| Accounts payable ($24, $, and $ to a related party) | $24.0M | $3.0M | -$1.0M |
| Deferred revenue (($240), ($56) and ($77) to a related party) | -$240.0M | -$56.0M | -$68.0M |
| Other liabilities | $8.0M | $25.0M | -$3.0M |
| Net cash used in operating activities | -$482.0M | -$170.0M | -$306.0M |
| Purchases of marketable securities | -$1.1B | -$1.0B | -$788.0M |
| Proceeds from maturities of marketable securities | $1.1B | $929.0M | $982.0M |
| Proceeds from sales of marketable securities | $71.0M | $36.0M | $24.0M |
| Purchases of property and equipment | -$2.0M | -$6.0M | -$24.0M |
| Net cash provided by (used in) investing activities | $66.0M | -$84.0M | $194.0M |
| Proceeds from issuance of common stock ($14, $228 and $20 from a related party), net | $429.0M | $228.0M | $25.0M |
| Proceeds from debt issuances, net | $49.0M | $47.0M | $0 |
| Proceeds from issuance of common stock pursuant to equity award plans | $10.0M | $9.0M | $8.0M |
| Payments of employee taxes related to net settlement of equity awards | $0 | -$7.0M | $0 |
| Net cash provided by financing activities | $488.0M | $277.0M | $33.0M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $72.0M | $23.0M | -$79.0M |
| Income taxes paid | $0 | $0 | $5.0M |
| Interest paid | $7.0M | $1.0M | $0 |
| Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities | $0 | $0 | $2.0M |
| Receivable from collaboration partners | $9.0M | $28.0M | $15.0M |
| Other assets | $5.0M | $22.0M | -$14.0M |
Timeline
Recent filings
- Sep 28, 2026CT ORDER
- Aug 24, 20264
- Aug 21, 2026144
- Aug 7, 2026SCHEDULE 13D/A
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jul 13, 20264
- Jul 9, 2026144
- Jun 24, 20264
- Jun 24, 2026144
- Jun 22, 2026144
- Jun 12, 20268-K
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitearcusbio.com1
- WikidataQ113503877
- SEC EDGARCIK 1724521
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataArcus Biosciences on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12